Establishment Labs
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 84.7m | 127m | 162m | 165m | 175m | 240m | 312m |
| % growth | (5 %) | 50 % | 28 % | 2 % | 6 % | 37 % | 30 % |
| EBITDA | (30.6m) | (31.4m) | (42.7m) | (58.3m) | (14.0m) | 11.3m | 41.7m |
| % EBITDA margin | (36 %) | (25 %) | (26 %) | (35 %) | (8 %) | 5 % | 13 % |
| Profit | (38.1m) | (41.1m) | (75.2m) | (78.5m) | (63.2m) | (32.5m) | (2.7m) |
| % profit margin | (45 %) | (32 %) | (47 %) | (48 %) | (36 %) | (14 %) | (1 %) |
| EV / revenue | 10.0x | 12.8x | 9.9x | 5.0x | 8.5x | 6.3x | 4.8x |
| EV / EBITDA | -27.7x | -51.6x | -37.4x | -14.0x | -106.4x | 134.5x | 36.1x |
| R&D budget | 13.8m | 18.3m | 20.3m | 26.4m | - | - | - |
| R&D % of revenue | 16 % | 14 % | 13 % | 16 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$20.0m | Late VC | ||
$15.0m | Debt | ||
$18.0m | Late VC | ||
$55.0m | Late VC | ||
| N/A | $66.9m Valuation: $332m 9.6x EV/LTM Revenues -14.8x EV/LTM EBITDA | IPO | |
| N/A | $69.0m | Post IPO Equity | |
* | $225m | Post IPO Debt | |
* | N/A | $78.7m | Post IPO Equity |
* | $50.0m | Private Placement VC | |
| Total Funding | $143m | ||
Related Content
Recent News about Establishment Labs
EditEstablishment Labs Holdings Inc. is a global medical technology firm that specializes in women's health and wellness. The company operates in the Femtech market, providing solutions for breast health, aesthetics, and reconstruction. Its clients are primarily women seeking breast reconstruction following cancer or those interested in aesthetic breast surgery.
The company's business model revolves around the development and sale of innovative medical devices. One of its flagship products is the Motiva Flora® tissue expander, the only one of its kind with an integrated port that is MRI conditional. This product is used to enhance results in breast reconstruction post-cancer. Another key product is Mia Femtech™, a minimally invasive procedure for achieving breast harmony.
Establishment Labs generates revenue through the sale of these products, which are backed by extensive research and development, with over 200 patent applications worldwide. The company is committed to creating a positive social, environmental, and economic impact with its products and corporate efforts.
The company recently welcomed Ross Mansbach as the General Counsel and Chief Compliance Officer. Mansbach brings a wealth of experience from his previous role at Avanos Medical, Inc., a publicly traded medical device company.
Keywords: Medical Technology, Women's Health, Femtech, Breast Health, Breast Aesthetics, Breast Reconstruction, Motiva Flora, Mia Femtech, Patent Applications, Corporate Social Responsibility.